Skip to main content
SpringerLink
Log in

Sitaxsentan sodium appears to be more cost effective than bosentan in treating patients with pulmonary arterial hypertension (PAH),

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Coyne T, Neild C, Morrow T.Management of pulmonary arterial hypertension with endothelin receptor antagonists: a pharmacoeconomic analysis. Proceedings of the American Thoracic Society 3 (Abstr. Suppl.): 417, Apr 2006

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sitaxsentan sodium appears to be more cost effective than bosentan in treating patients with pulmonary arterial hypertension (PAH),. Pharmacoecon. Outcomes News 508, 7 (2006). https://doi.org/10.2165/00151234-200605080-00018

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200605080-00018

Keywords

Search

Navigation